ATE369874T1 - Botulinustoxin-therapie für hauterkrankungen - Google Patents

Botulinustoxin-therapie für hauterkrankungen

Info

Publication number
ATE369874T1
ATE369874T1 AT04813630T AT04813630T ATE369874T1 AT E369874 T1 ATE369874 T1 AT E369874T1 AT 04813630 T AT04813630 T AT 04813630T AT 04813630 T AT04813630 T AT 04813630T AT E369874 T1 ATE369874 T1 AT E369874T1
Authority
AT
Austria
Prior art keywords
skin diseases
toxin therapy
botulin toxin
botulin
therapy
Prior art date
Application number
AT04813630T
Other languages
English (en)
Inventor
Eric First
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE369874T1 publication Critical patent/ATE369874T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT04813630T 2003-12-09 2004-12-08 Botulinustoxin-therapie für hauterkrankungen ATE369874T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/731,973 US8048423B2 (en) 2003-12-09 2003-12-09 Botulinum toxin therapy for skin disorders

Publications (1)

Publication Number Publication Date
ATE369874T1 true ATE369874T1 (de) 2007-09-15

Family

ID=34634457

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07010256T ATE446769T1 (de) 2003-12-09 2004-12-08 Botulintoxin-therapie für hauterkrankungen
AT04813630T ATE369874T1 (de) 2003-12-09 2004-12-08 Botulinustoxin-therapie für hauterkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07010256T ATE446769T1 (de) 2003-12-09 2004-12-08 Botulintoxin-therapie für hauterkrankungen

Country Status (10)

Country Link
US (1) US8048423B2 (de)
EP (2) EP1691830B1 (de)
JP (1) JP4937758B2 (de)
AT (2) ATE446769T1 (de)
AU (1) AU2004296870B2 (de)
BR (1) BRPI0417493B8 (de)
CA (1) CA2549550C (de)
DE (2) DE602004023886D1 (de)
ES (2) ES2289591T3 (de)
WO (1) WO2005056050A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20080008777A1 (en) * 2004-02-12 2008-01-10 Philip Radovic Methods of treating a bunion
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
ATE533853T1 (de) * 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
EP2298339B1 (de) * 2004-09-23 2015-07-15 Toxcure, Inc. Behandlung von Neoplasmen mit Neurotoxin
US20060067950A1 (en) * 2004-09-27 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in wound healing
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
JP6444032B2 (ja) * 2011-01-07 2018-12-26 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療用又は美容用毒素組成物の局所塗布、除去及び不活化のための方法及びキット
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
CN105451710A (zh) 2013-03-22 2016-03-30 利普泰股份公司 用于治疗和/或护理皮肤、粘膜和/或指甲的外泌多糖
JP2020510100A (ja) 2017-03-13 2020-04-02 フィリップ アンドリュー ラドヴィッチ 足の第１中足趾節関節の異常の治療に使用するための神経筋毒素
JP7096845B2 (ja) * 2017-05-31 2022-07-06 アラーガン、インコーポレイテッド メラノサイトの活動亢進および／または過剰メラニンに関連する障害の治療のためのボツリヌス神経毒素

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE69620888T2 (de) * 1996-11-27 2002-08-14 William J Binder Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
ATE314859T1 (de) * 1998-10-27 2006-02-15 Mayo Foundation Botulinumtoxine zur verstärkung der wundheilung
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CA2451923C (en) 2001-07-27 2009-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
EP1534376B1 (de) * 2002-06-25 2016-08-31 Theraject, Inc. Sich schnell auflösender mikroperforator für die medikamentenabgabe und andere anwendungen
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Also Published As

Publication number Publication date
ES2289591T3 (es) 2008-02-01
BRPI0417493A (pt) 2007-05-29
WO2005056050A1 (en) 2005-06-23
JP2007513964A (ja) 2007-05-31
BRPI0417493B8 (pt) 2021-05-25
AU2004296870B2 (en) 2010-05-20
DE602004008329D1 (de) 2007-09-27
DE602004008329T2 (de) 2008-05-08
DE602004023886D1 (de) 2009-12-10
CA2549550A1 (en) 2005-06-23
EP1691830B1 (de) 2007-08-15
ATE446769T1 (de) 2009-11-15
EP1820510A1 (de) 2007-08-22
EP1691830A1 (de) 2006-08-23
JP4937758B2 (ja) 2012-05-23
AU2004296870A1 (en) 2005-06-23
US20050123567A1 (en) 2005-06-09
CA2549550C (en) 2012-07-17
US8048423B2 (en) 2011-11-01
ES2335310T3 (es) 2010-03-24
BRPI0417493B1 (pt) 2018-11-13
EP1820510B1 (de) 2009-10-28

Similar Documents

Publication Publication Date Title
ATE369874T1 (de) Botulinustoxin-therapie für hauterkrankungen
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
PL414996A1 (pl) Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do wytwarzania leku do leczenia litych guzów ośrodkowego układu nerwowego
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
DE50310516D1 (de) Fredericamycin-derivate
DE60134324D1 (de) NEUE HEILMITTEL FüR KREBS
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ATE303157T1 (de) Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
MXPA03006110A (es) Metodo de tratamiento para enfermedades o condiciones por desmielinizacion.
WO2004110420A8 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
SE0101082D0 (sv) Novel use
WO2003084476A3 (en) Treatment of lung disorder
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
SE0002739D0 (sv) New use
SE0200198D0 (sv) New use
BRPI0509478A (pt) tratamento de ferida por pressão
PT1133295E (pt) Utilizacao da nicergolina no tratamento da espasticidade
NZ594945A (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties